X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Dompé farmaceutici and FarmaMondo have inked Managed Access Program distribution agreement appointing the FarmaMondo as the exclusive partner to make Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis in Russia and other CIS countries.
Lead Product(s): Cenegermin
Therapeutic Area: Ophthalmology Product Name: Oxervate
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dompe Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 26, 2020
Details:
The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, and Uzbekistan).
Lead Product(s): Cenegermin
Therapeutic Area: Ophthalmology Product Name: Oxervate
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dompe Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
